Literature DB >> 1657376

The protooncogene c-myb increases the expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor messenger RNAs by a transcriptional mechanism.

K Reiss1, A Ferber, S Travali, P Porcu, P D Phillips, R Baserga.   

Abstract

The protooncogene c-myb is the cellular equivalent of the viral transforming oncogene v-myb. When human c-myb is constitutively expressed in Balb/c3T3 cells it abrogates their absolute requirement for insulin-like growth factor 1 (IGF-1). We show now, in two different cell lines, that the constitutive expression of the protooncogene c-myb causes an increase in both IGF-1 and IGF = 1 receptor mRNA levels. This increase in mRNA levels is due, at least in part, to an increase in the rate of transcription since, by run-on assay, cells carrying the human c-myb cDNA show a 3-fold increase in transcriptional rates in comparison to the control parent cell lines. The increased expression of IGF-1 receptor mRNA also results in an increased number of IGF-1 binding sites per cell. Although some oncogenes have been described that are homologous to growth factors, or growth factor receptors, c-myb seems to represent a novel way of oncogene action inasmuch as it increases the expression of both a growth factor receptor and its ligand, thus establishing a quasi-autocrine mechanism which modifies the growth factor requirements of the cell and its growth regulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657376

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Apoptosis induced by anticancer drugs.

Authors:  J A Hickman
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

Review 2.  The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.

Authors:  M Davies; S Gupta; G Goldspink; M Winslet
Journal:  Int J Colorectal Dis       Date:  2005-06-16       Impact factor: 2.571

Review 3.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  Insulin-like growth factor 1 activates methionine adenosyltransferase 2A transcription by multiple pathways in human colon cancer cells.

Authors:  Heping Yang; Tony W H Li; Jian Peng; José M Mato; Shelly C Lu
Journal:  Biochem J       Date:  2011-06-01       Impact factor: 3.857

5.  A-myb is expressed in bovine vascular smooth muscle cells during the late G1-to-S phase transition and cooperates with c-myc to mediate progression to S phase.

Authors:  D J Marhamati; R E Bellas; M Arsura; K E Kypreos; G E Sonenshein
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

6.  The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulinlike growth factor 1 with its receptor.

Authors:  P Porcu; A Ferber; Z Pietrzkowski; C T Roberts; M Adamo; D LeRoith; R Baserga
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

7.  Characterization of insulin-like growth factor I binding sites in human bladder cancer cell lines.

Authors:  M Iwamura; M Ishibe; P M Sluss; A T Cockett
Journal:  Urol Res       Date:  1993-01

8.  Roles of insulinlike growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells.

Authors:  Z Pietrzkowski; C Sell; R Lammers; A Ullrich; R Baserga
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

9.  Overexpression of C-terminally but not N-terminally truncated Myb induces fibrosarcomas: a novel nonhematopoietic target cell for the myb oncogene.

Authors:  R D Press; E P Reddy; D L Ewert
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

10.  Oncogenic truncation of the first repeat of c-Myb decreases DNA binding in vitro and in vivo.

Authors:  P W Dini; J S Lipsick
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.